Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Venous Thromboembolism 1Pulmonary Embolism 1Multiple Myeloma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 170Rituximab 143Specimen Handling 82venetoclax 79fludarabine 79obinutuzumab 67Vincristine 67Doxorubicin 65Biopsy 64Prednisone 63Magnetic Resonance Spectroscopy 63zanubrutinib 52Lenalidomide 52Dexamethasone 48Cytarabine 43Methotrexate 42blinatumomab 40Immunotherapy, Adoptive 38acalabrutinib 37Bendamustine Hydrochloride 37Etoposide 32fludarabine phosphate 31ibrutinib 28glofitamab 28polatuzumab vedotin 26pirtobrutinib 24orelabrutinib 24Gemcitabine 23Injections 21pembrolizumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × enoxaparin sodium × Lymphoid × Clear all
NCT07270263 2025-12-26

HEM-DOAC

Medical University of Gdansk

Phase NA Recruiting
100 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Pulmonary Embolism, Hematologic Neoplasms, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡